Quince Therapeutics Inc. has announced its participation in the upcoming 2025 A-T Clinical Research Conference organized by the A-T Society in the United Kingdom. During the event, Quince will provide updates on its pivotal Phase 3 NEAT clinical trial, which is focused on evaluating the neurological effects of eDSP treatment in patients with Ataxia-Telangiectasia (A-T). The trial, currently in the enrollment phase, has secured 99 participants to date. Key opinion leaders at the conference will present post hoc data analyses from Quince's prior Phase 3 ATTeST clinical trial. Topline results from the NEAT trial are expected to be reported in the first quarter of 2026, with a potential New Drug Application (NDA) submission to the FDA anticipated in the second half of 2026, contingent on positive outcomes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。